The Stop Funding Genital Mutilation Act amends the Social Security Act to prohibit Medicaid and CHIP funding for gender transition procedures. It adds a new funding-exclusion category to Medicaid and expands the same restriction to CHIP, with a comprehensive definition of what counts as a “specified gender transition procedure.” The bill also includes limited exceptions for certain medical circumstances.
The change would redirect state and federal dollars away from coverage of transition-related care, with wide-reaching implications for patients, providers, and state health programs.
At a Glance
What It Does
The bill adds a new exclusion (paragraph 28) to Medicaid funding prohibitions and mirrors that exclusion for CHIP. It also defines “specified gender transition procedures” in new 1905(kk), detailing surgeries, implants, and accompanying medications that would be covered by the prohibition.
Who It Affects
State Medicaid programs and CHIP administrators, healthcare providers that perform transition-related care, and individuals enrolled in Medicaid or CHIP who seek such procedures.
Why It Matters
This creates a federal policy stance on coverage for gender transition care, potentially reducing access for low-income individuals and shaping state program design and budgeting for decades to come.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill targets federal funding for gender transition care by amending the Social Security Act’s Medicaid and CHIP provisions. It introduces a new exclusion (28) in Medicaid and aligns CHIP to exclude funding for the same set of procedures, ensuring that neither program pays for specified gender transition procedures.
To determine what counts, the bill defines these procedures in a new subsection (kk) of the Social Security Act, listing surgeries, implants, and medications that would qualify for exclusion. The definition covers a broad range of surgical operations (including mastectomy, vaginoplasty, phalloplasty, and related reconstructions), implants in the chest or buttocks, and medications such as puberty-blocking drugs and hormones administered at high doses.
There are explicit exceptions within the definition: puberty suppression for precocious puberty, medically necessary treatments for disorders of sex development or other conditions, and certain emergency or restorative procedures after prior surgeries. The terminology for “sex” is anchored to biological determinants, with explicit male and female definitions.
In practice, states would need to modify their Medicaid and CHIP plans to ensure no funding is used for these procedures, which could affect the level of care available to low-income transgender individuals and influence provider charges and patient access. Policymakers, plan administrators, and providers should anticipate administrative adjustments, potential shifts in demand for gender-transition services, and the need for alternative care pathways for affected patients.
The Five Things You Need to Know
The bill creates a new prohibited expenditure category (1903(i)(28)) for specified gender transition procedures.
CHIP funding is amended to include the same prohibition (2107(e)(1)(N) → add (28)).
Specified gender transition procedures are defined in 1905(kk) and include a wide list of surgeries, implants, and medications.
There are explicit exceptions for certain medical circumstances (e.g.
precocious puberty treatment and disorders of sex development).
The definitions of sex, female, and male anchor the scope of what is considered a transition procedure and thus what is prohibited.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Medicaid funding prohibition
Section 2(a) amends 1903(i) to add a new paragraph (28) that restricts payments for specified gender transition procedures. This creates a categorical exclusion in Medicaid funding for those procedures, aligning Medicaid with the policy goal of prohibiting coverage for transition-related care under the program.
CHIP funding prohibition
Section 2(b) amends 2107(e)(1)(N) to strike (17) and insert (28), extending the same funding prohibition to the CHIP program. This ensures CHIP cannot fund the defined procedures in the same way as Medicaid.
Definition of specified gender transition procedures
Section 2(c) adds 1905(kk) to define “specified gender transition procedures.” It enumerates surgeries, implants, and medications intended to change body characteristics to align with the individual’s sex, and includes explicit examples ranging from mastectomy and various genital surgeries to puberty-blocking drugs and hormone therapies at supraphysiologic doses. The definition also provides a limited exception framework (paragraph (2)) for certain medical circumstances.
Sex definitions and exceptions
Section 2(d) clarifies the terms ‘sex,’ ‘female,’ and ‘male’ for purposes of paragraph (1). It sets forth the biological definitions that underlie the scope of the prohibition and the exceptions, including conditions like disorders of sex development and situations where immediate medical risk warrants a procedure.”
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State Medicaid agencies may realize cost containment by excluding funding for transition procedures.
- Federal taxpayers could see reduced expenditures through lower federal requests for Medicaid/CHIP funding tied to transition-care coverage.
- Budget and health-policy decision-makers may gain a clearer, though controversial, framework for prioritizing limited health dollars.
- Research and policy observers tracking Medicaid spending could analyze shifts in coverage and utilization patterns.
Who Bears the Cost
- Individuals enrolled in Medicaid or CHIP who would have sought gender transition procedures may face coverage gaps and increased out-of-pocket costs.
- Healthcare providers who perform transition-related surgeries, implants, or prescribing therapies may see reduced demand and revenue.
- States may experience administrative complexity and potential access issues for low-income populations requiring transition-related care.
- Communities relying on Medicaid/CHIP-funded services could see broader access disparities in gender-transition care.
Key Issues
The Core Tension
The central dilemma is whether and how to restrict public funding for gender transition care while ensuring medically necessary services remain accessible to vulnerable populations in the absence of federal funding.
The bill creates a straightforward fiscal constraint on funding for gender transition procedures, which raises policy tensions around access to care, medical necessity, and the evolving evidence base for transgender health. The broad definition of “specified gender transition procedures” captures a wide range of surgical and medical interventions, but the added exceptions seek to mitigate perceived overreach in specific medical circumstances.
Practically, states will need to adjust their Medicaid and CHIP benefit designs and provider networks, potentially shifting where and how patients receive care. The balance between fiscal discipline and patient access will hinge on how state programs interpret and implement the exceptions and how providers navigate patient needs within tighter funding limits.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.